Source comparison
Ipamorelin Safety Studies: Short-Term vs Extended Exposure Data
Single-dose (Phase 1) 0.03–3.0 mcg/kg SC, single administration Vital signs, ECG, cortisol/prolactin, injection-site reaction 8% mild injection-site erythema; 0% serious AEs Established NOAEL at 1.5 mcg/kg; no endocrine disruption at therapeutic range 4-week d
This comparison does not assign a generated winner or score.
- Single-dose (Phase 1)
- 0.03–3.0 mcg/kg SC, single administration
- Vital signs, ECG, cortisol/prolactin, injection-site reaction
- 8% mild injection-site erythema; 0% serious AEs
- Established NOAEL at 1.5 mcg/kg; no endocrine disruption at therapeutic range
- 4-week daily dosing (Phase 2)
- 0.5, 1.0, 1.5 mcg/kg SC daily
- Growth hormone response, cortisol, prolactin, metabolic panel
- 12% transient injection-site discomfort; 0% systemic AEs
- Confirmed receptor selectivity; no tachyphylaxis or desensitization observed
- 16-week daily dosing (Phase 2 extension)
- 1.0 mcg/kg SC daily
- IGF-1 levels, body composition, comprehensive metabolic panel, cardiovascular monitoring
- 14% mild injection-site reactions; 1 participant withdrew due to unrelated illness
- Long-term tolerability validated; growth hormone pulsatility maintained without receptor downregulation
- Comparative study vs hexarelin
- Equimolar dosing (1.0 mcg/kg)
- Cortisol, ACTH, prolactin, growth hormone peak
- Ipamorelin: 8% mild AEs; Hexarelin: 70% cortisol elevation, 45% tachycardia
- Ipamorelin's selective mechanism eliminates off-target endocrine activation seen with non-selective agonists